Karpathakis et al. (2016) conducted a complete molecular identification of small intestinal neuroendocrine tumors (SINETs) and found that CELSR3 has a significant epigenetic mutation that might be a potential drug target. Here, CELSR3 is linked to small intestine neuroendocrine neoplasm.